Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50

Benzinga Newsdesk www.benzinga.com Neutral 65.5%

Neg 0% Neu 65.5% Pos 0%

Citigroup analyst Brendan Digan maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $45 to $50.